Beneficial effects of andrographolide in a rat model of autoimmune myocarditis and its effects on PI3K/Akt pathway

The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology
Qi ZhangGuang Yan

Abstract

The study is to investigate effects of andrographolide on experimental autoimmune myocarditis (EAM). Lewis rats were immunized on day 0 with porcine cardiac myosin to establish EAM. The EAM rats were treated with either andrographolide (25, 50, 100 mg/kg/day) or vehicle for 21 days. An antigen-specific splenocytes proliferation assay was performed by using the cells from control rats immunized with cardiac myosin. Survival rates, myocardial pathology and myocardial functional parameters (left ventricle end-diastolic pressure, ± dP/dt and left ventricular internal dimension) of EAM rats received andrographolide were significantly improved. Andrographolide treatment caused an decrease in the infiltration of CD3+ and CD14+ positive cells in myocardial tissue. Moreover, andrographolide treatment caused a reduction in the plasma levels of tumor necrosis factor-alpha, interleukin-17 (IL-17) and myosin-antibody, and an increase in the level of IL-10 in EAM rats. Oral administration of andrographolide resulted in the decreased expression of p-PI3K, p-Akt without any change of PI3K and Akt. Further results indicate andrographolide significantly inhibited myosin-induced proliferation in splenocytes, and this effect was inhibited by co-tr...Continue Reading

References

Nov 15, 1991·The American Journal of Cardiology·Y DroryM R Kramer
Sep 19, 2002·Proceedings of the National Academy of Sciences of the United States of America·Gianluigi CondorelliJohn Ross
Aug 3, 2005·The Journal of Clinical Investigation·Ichiro ShiojimaKenneth Walsh
Apr 26, 2006·Circulation·Brian DeBoschAnthony J Muslin
Nov 16, 2007·Biochemical Pharmacology·Punniyakoti T VeeraveeduYoshifusa Aizawa
Jan 5, 2008·The Journal of Pharmacology and Experimental Therapeutics·Anthony Y H WooChristopher H K Cheng
Jul 5, 2008·European Journal of Heart Failure·Christian StumpfChristoph D Garlichs
Oct 25, 2011·Clinical and Experimental Pharmacology & Physiology·Jonathan Chee Woei LimW S Fred Wong
Dec 22, 2011·Lancet·Sandeep SagarLeslie T Cooper
Mar 24, 2012·Heart·Chantal ElammLeslie T Cooper
Jul 3, 2013·Journal of Autoimmunity·Andrew H Lichtman
Aug 19, 2014·Journal of Cellular and Molecular Medicine·Zhang-Wei ChenJun-Bo Ge
Jan 1, 2015·Circulation. Heart Failure·Clemens DuerrschmidSandra B Haudek
Sep 1, 2015·Frontiers in Pharmacology·Alessandra Ghigo, Mingchuan Li
Nov 5, 2015·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Jinlong ZhangYunfeng Ju
Apr 6, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xuefei LiuHaitao Yuan
May 4, 2016·Current Research in Translational Medicine·H S LiuZ-W Wang
Jul 2, 2016·JCI Insight·Jennifer M MyersMadeleine W Cunningham
Aug 28, 2016·Biochimica Et Biophysica Acta·Sheng-An SuMeixiang Xiang

❮ Previous
Next ❯

Citations

May 13, 2020·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Shoufan WangAiqin Xu
May 13, 2020·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Shoufan WangAiqin Xu

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
light microscopy

Software Mentioned

image pro plus
Image J
SPSS

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.